Context Therapeutics Inc.
CNTX
$0.775
$0.0020.26%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.85% | 10.67% | -6.96% | -13.21% | -6.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.83% | 202.59% | -41.64% | -42.65% | 78.58% |
| Operating Income | 37.83% | -202.59% | 41.64% | 42.65% | -78.58% |
| Income Before Tax | 50.62% | -197.20% | 55.01% | 41.86% | -90.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 50.62% | -197.20% | 55.01% | 41.86% | -90.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 50.62% | -197.20% | 55.01% | 41.86% | -90.34% |
| EBIT | 37.83% | -202.59% | 41.64% | 42.65% | -78.58% |
| EBITDA | 37.85% | -202.69% | 41.65% | 42.66% | -78.67% |
| EPS Basic | 90.38% | 41.04% | 86.94% | 41.86% | -90.31% |
| Normalized Basic EPS | 90.38% | 41.04% | 86.95% | 41.84% | -90.37% |
| EPS Diluted | 80.33% | 41.04% | 86.94% | 41.86% | -90.31% |
| Normalized Diluted EPS | 90.38% | 41.04% | 86.95% | 41.84% | -90.37% |
| Average Basic Shares Outstanding | 413.15% | 404.07% | 244.22% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 413.15% | 404.07% | 244.22% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |